Wolfing Shay sold $1.4M of NVMI

Wolfing Shay (CTO) sold 3,864 shares of NOVA LTD. (NVMI) at $363.28 ($1.40M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wolfing Shay
Published Sep 22, 2026, 1:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NVMI
Bearish
medium confidence
Mentioned
$NVMI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVMIBearishLow
01

Why it matters

The CTO's sale reduces insider ownership, which may be interpreted by the market as a lack of confidence, though it could be a pre‑planned liquidity event.

02

Market read

Primary disclosure of a significant insider sale; modest trading relevance for NVMI shareholders.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 5/10Novelty 5/10Timing: post‑market filing on 2026‑09‑22

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$NVMIBearishMedium confidence
Context

CTO Wolfing Shay sold 3,864 shares for $1.4M via a 10b5-1 plan, reducing his stake to 21,409 shares.

Expected impact

Possible modest dip in NVMI price over the next few days.

Evidence & confidence

CTO is a senior insider; sale size is notable for a micro‑cap, but no other catalyst is present.

Market effects

Minimal impact on the broader biotech sector.

Limited to investors tracking NVMI.

None

Counterpoint

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • NOVA LTD.

    Biotech company listed under ticker NVMI.

  • Wolfing Shay

    Chief Technology Officer of NOVA LTD.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVMIMed

Nova Q3 Earnings Call Highlights

Nova (NVMI) reported strong Q3 results, with record advanced packaging sales and significant demand for its WMC platform. Logic and foundry accounted for 61% of product revenue. The company forecasted Q4 revenue of $305M-$315M and expects GAAP EPS of $2.78-$2.94. Nova ended Q3 with $1.8B in cash and repurchased $38.5M of shares. It plans to discuss future strategy at an investor day in March 2027.

$NVMIMed

Nova Ltd (NVMI) Q3 2026 Earnings Call Highlights: Record Revenue, $1 Billion Milestone

Nova Ltd (NVMI) reported record Q3 2026 revenue, reaching $1 billion. The company faces supply chain constraints and expects new competition in materials metrology. Gross margin is guided to remain flat at 59%. Operating expenses are expected to increase in Q4 2026 due to higher R&D spending. CEO Gabriel Waisman highlighted growth opportunities in memory and gate-all-around metrology, with strong demand for the Metrion tool despite longer lead times.

$NVMIHighAI 8/10

Nova (NVMI) Q3 2026 Earnings Call Transcript

Nova (NVMI) reported Q3 2026 revenue of $287.8M, up 13% QoQ and 28% YoY, driven by strong demand in memory, advanced packaging, and logic segments. The company expects to exceed $1B in annual revenue, a year ahead of plan. Q4 guidance projects revenue between $305M-$315M and EPS between $2.78-$2.94 (GAAP) and $3.03-$3.18 (non-GAAP).